• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Mirum Pharmaceuticals Inc.

    9/9/25 4:47:34 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIRM alert in real time by email
    S-8 1 mirm-sx820250909.htm S-8 Document

    As filed with the Securities and Exchange Commission on September 9, 2025
    Registration No. 333-
    ______________________________________________________________________________________________________________
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    ______________________________________________________________________________________________________________
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
    ______________________________________________________________________________________________________________
    Mirum Pharmaceuticals, Inc.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Delaware
    83-1281555
    (State or other jurisdiction of incorporation or organization)
    (I.R.S. Employer Identification No.)
    989 East Hillsdale Boulevard, Suite 300
    Foster City, California

    94404
    (Address of Principal Executive Offices)
    (Zip Code)
    ______________________________________________________________________________________________________________
    2020 Inducement Plan
    (Full titles of the plans)
    ______________________________________________________________________________________________________________
    Christopher Peetz
    Chief Executive Officer
    Mirum Pharmaceuticals, Inc.
    989 East Hillsdale Boulevard
    Suite 300
    Foster City, California 94404 (650) 667-4085
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    ______________________________________________________________________________________________________________
    Copies to:
    Jason L. Kent
    Julia R. Boesch
    Cooley LLP
    55 Hudson Yards
    New York, New York
    (212) 479-6000
    ______________________________________________________________________________________________________________
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer
    ☒
    Accelerated filer
    ☐
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE
    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Mirum Pharmaceuticals, Inc. (the “Registrant”) for the purpose of registering 1,500,000 additional shares of the Registrant’s common stock, par value $0.0001 (“Common Stock”), under the Registrant’s 2020 Inducement Plan (the “2020 Inducement Plan”) for an aggregate of 5,500,000 shares of Common Stock issuable under the 2020 Inducement Plan, pursuant to approval of the Compensation Committee of the Registrant’s Board of Directors.
    These additional shares of Common Stock are securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.
    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
    Item 3. Incorporation of Documents by Reference.
    The Registrant previously registered shares of Common Stock for issuance under the 2020 Inducement Plan pursuant to (i) a Registration Statement on Form S-8 (File No. 333-238086) filed with the Securities and Exchange Commission (the “Commission”) on May 7, 2020, (ii) a Registration Statement on Form S-8 (File No. 333-254043) filed with the Commission on March 9, 2021, (iii) a Registration Statement on Form S-8 (File No. 333-263397) filed with the Commission on March 9, 2022 and (iv) a Registration Statement on Form S-8 (File No. 333-275283) filed with the Commission on November 2, 2023 (collectively, the “Prior Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference.
    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:
    (a)The Registrant’s Annual Report on Form 10-K, filed with the Commission on February 26, 2025 (and any portions of the Registrant’s Definitive Proxy Statement on Schedule 14A filed on April 14, 2025, that are incorporated by reference into its Annual Report on Form 10-K for the year ended December 31, 2024);
    (b)The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the Commission on May 7, 2025 and August 6, 2025 respectively;
    (c)The description of the Registrant’s Common Stock contained in the Registrant’s Registration Statement on Form 8-A (File No. 001-38981) filed with the Commission on July 15, 2019 under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description, including Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on March 15, 2024; and
    (d)The Registrant’s Current Report on Form 8-K (other than information furnished rather than filed) filed with the Commission on May 30, 2025.
    All documents filed by the Registrant with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement unless specifically stated to the contrary. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.



    Item 8. Exhibits.
    The exhibits to this Registration Statement are listed below:
    Exhibit
     Number

        Description    
    4.1

    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on July 25, 2019).
    4.2

    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on July 25, 2019).
    4.3

    Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-232251), filed with the Commission on July 8, 2019).
    5.1
    Opinion of Cooley LLP.
    23.1
    Consent of Independent Registered Public Accounting Firm.
    23.2
    Consent of Cooley LLP (included in Exhibit 5.1).
    24.1
    Power of Attorney (included on the signature page).
    99.1

    Mirum Pharmaceuticals, Inc. 2020 Inducement Plan, as amended September 4, 2025.
    107

    Filing Fee Table.





    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on September 9, 2025.


    MIRUM PHARMACEUTICALS, INC.
    By:    /s/ Christopher Peetz    
    Christopher Peetz
    Chief Executive Officer





    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher Peetz, Eric Bjerkholt and Douglas Sheehy, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

    Signature
    Title
    Date
    /s/ Christopher Peetz
    Chief Executive Officer and Director
    (Principal Executive Officer)
    September 9, 2025
    Christopher Peetz
    /s/ Eric Bjerkholt
    Chief Financial Officer
    (Principal Financial Officer)
    September 9, 2025
    Eric Bjerkholt
    /s/ Jody HoweSenior Vice President, Global Controller
    (Principal Accounting Officer)
    September 9, 2025
    Jody Howe
    /s/ Laura BregeDirector
    September 9, 2025
    Laura Brege
    /s/ Lon Cardon, Ph.D.Director
    September 9, 2025
    Lon Cardon, Ph.D.
    /s/ William C. FaireyDirector
    September 9, 2025
    William C. Fairey
    /s/ Laurent Fischer, M.D.Director
    September 9, 2025
    Laurent Fischer, M.D.
    /s/ Michael GreyDirector
    September 9, 2025
    Michael Grey
    /s/ Patrick HeronDirector
    September 9, 2025
    Patrick Heron
    /s/ Saira Ramasastry, M.S., M.Phil.Director
    September 9, 2025
    Saira Ramasastry, M.S., M.Phil.
    /s/ Timothy WalbertDirector
    September 9, 2025
    Timothy Walbert


    Get the next $MIRM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MIRM

    DatePrice TargetRatingAnalyst
    8/11/2025$89.00Buy
    Stifel
    5/19/2025$73.00Buy
    H.C. Wainwright
    4/17/2024$48.00Buy
    Stifel
    12/18/2023$60.00 → $58.00Buy
    H.C. Wainwright
    11/20/2023$37.00Overweight
    Analyst
    11/13/2023$60.00Overweight
    Morgan Stanley
    10/24/2023$50.00Overweight
    Cantor Fitzgerald
    10/17/2023$62.00Outperform
    Evercore ISI
    More analyst ratings

    $MIRM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

    - Topline data announcement expected second quarter of 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT inhibitor, for the treatment of cholestatic pruritus in patients with primary sclerosing cholangitis (PSC). The trial previously met its pre-specified efficacy and safety thresholds at the blinded interim analysis for dose selection conducted in 2024 and topline results are expected to be announced in the second quarter of 2026. "Completing enrollment in VISTAS is a major milestone for the PSC community and for Mirum," said Joanne Quan, M.D., Chief Medical Officer. "This

    9/8/25 8:00:00 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Citi Biopharma Back-to-School Summit on Wednesday, September 3rd Cantor Global Healthcare Conference 2025 Company presentation - Thursday, September 4th starting at 3:20 p.m. ET Morgan Stanley 23nd Annual Global Healthcare Conference Company presentation - Monday, September 8th starting at 8:30 a.m. ET Baird 2025 Global Healthcare Conference on Tuesday, September 9th H.C.

    8/27/25 4:02:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    - Second quarter 2025 total revenue of $128 million - 2025 revenue guidance increased to $490 to $510 million - Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the second quarter 2025 and provided a business update. "Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch," said Chris Peetz, chief executive officer of Mirum. "The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients tha

    8/6/25 4:01:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J bought $24,214 worth of shares (549 units at $44.11) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    3/18/25 5:04:31 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $99,518 worth of shares (2,298 units at $43.31) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    3/12/25 4:51:20 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $83,661 worth of shares (1,915 units at $43.69) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    3/10/25 5:12:58 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Bjerkholt Eric sold 8,000 shares and exercised 2,954 shares at a strike of $26.49, decreasing direct ownership by 14% to 31,190 units (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    8/12/25 8:00:03 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Peetz Christopher exercised 40,000 shares at a strike of $2.94 and sold $2,480,000 worth of shares (40,000 units at $62.00) (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    8/12/25 7:57:57 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, GLOBAL CONTROLLER Howe Jolanda sold $580,000 worth of shares (10,000 units at $58.00) and exercised 10,000 shares at a strike of $6.27 (SEC Form 4)

    4 - Mirum Pharmaceuticals, Inc. (0001759425) (Issuer)

    8/8/25 4:50:40 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    SEC Filings

    View All

    SEC Form S-8 filed by Mirum Pharmaceuticals Inc.

    S-8 - Mirum Pharmaceuticals, Inc. (0001759425) (Filer)

    9/9/25 4:47:34 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Mirum Pharmaceuticals Inc.

    144 - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    9/8/25 4:06:55 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Mirum Pharmaceuticals Inc.

    SCHEDULE 13D/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    8/20/25 5:17:53 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Mirum Pharmaceuticals with a new price target

    Stifel resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $89.00

    8/11/25 10:05:47 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Mirum Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $73.00

    5/19/25 8:53:13 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Mirum Pharmaceuticals with a new price target

    Stifel initiated coverage of Mirum Pharmaceuticals with a rating of Buy and set a new price target of $48.00

    4/17/24 7:27:53 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

    For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

    2/21/25 11:48:20 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 4:37:52 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 12:55:40 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mirum Pharmaceuticals Inc.

    SC 13G/A - Mirum Pharmaceuticals, Inc. (0001759425) (Subject)

    11/14/24 12:25:52 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIRM
    Leadership Updates

    Live Leadership Updates

    View All

    Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

    5/19/25 8:30:00 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates

    - 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

    1/13/25 8:30:00 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

    SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

    3/25/24 7:00:00 AM ET
    $IPSC
    $MIRM
    $RPHM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MIRM
    Financials

    Live finance-specific insights

    View All

    Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    - Second quarter 2025 total revenue of $128 million - 2025 revenue guidance increased to $490 to $510 million - Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the second quarter 2025 and provided a business update. "Our second quarter results once again underscore the strength of our commercial programs with notable outperformance from our International business and U.S. PFIC launch," said Chris Peetz, chief executive officer of Mirum. "The momentum we are seeing with Livmarli globally reinforces our belief that the medicine will reach and help more patients tha

    8/6/25 4:01:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

    Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that it will report second quarter 2025 financial results on August 6, 2025. Mirum will also host a conference call to discuss the second quarter 2025 financial results and recent corporate progress. Conference call details: Wednesday, August 6th, 2025 4:30 p.m. ET / 1:30 p.m. PT Dial-In: U.S./Toll-Free: +1 833 470 1428 International: +1 404 975 4839 Access Code: 448461 You may also access the call via webcast by visiting the Events & Presentations section on Mirum's website. A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical

    7/30/25 4:01:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    - First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million - VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 - LIVMARLI oral tablet formulation FDA approved - Conference call to provide business updates today, May 7 at 1:30 p.m. PT/4:30 p.m. ET Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today reported financial results for the first quarter 2025 and provided a business update. "It's been a strong start to the year with commercial growth and multiple milestones achieved across our pipeline," said Chris Peetz, chief executive officer of Mirum. "We're pleased with the FD

    5/7/25 4:01:00 PM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care